Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06748872

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma (EPITOME-1015-I)

EPITOME-1015-I: a Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of a Third Generation TCR-T Therapy, MDG1015, in Epithelial Ovarian Carcinoma, Gastroesophageal (Junction) Adenocarcinoma, Myxoid (Round Cell) Liposarcoma And/or Synovial Sarcoma Subjects with Advanced Disease Expressing NY-ESO-1 And/or LAGE-1a

Sponsor: Medigene AG

Conditions Epithelial Ovarian Cancer Gastro-esophageal Junction Cancer Myxoid Liposarcoma Soft Tissue Sarcoma (STS) Synovial Sarcoma

Interventions Lymphodepletion TCR-T cells (MDG1015)

Updated 1 time since 2025 Last updated: Dec 23, 2024 Started: Jul 1, 2025 Primary completion: Dec 1, 2027 Completion: Aug 1, 2042

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Epithelial Ovarian Cancer and Gastro-esophageal Junction Cancer and is currently actively recruiting participants. Medigene AG leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medigene AG

Data source: Medigene AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States